VEGFA and neoplasm: Bevacizumab is a VEGF monoclonal antibody, and when used in combination with ICIs, it can change the microenvironment to an immune stimulatory environment by improving priming and activation of T cells, tumor infiltration of T cells, and inhibiting cells that lead to immune suppression [79].